Decreased level of reduced glutathione (GSH) were found in CF epithelial lining fluid and anecdotal evidence suggested improved lung function after GSH-inhalation. In a double-blind, placebo-controlled, randomized clinical trial we investigated the safety and efficacy of inhaled glutathione. Of 153 subjects (age 8 years, FEV1 40%, 90%) 73 inhaled glutathione (646 mg GSH-Na) over 24 wks via a specialized e-flow device twice daily and 80 used placebo (0.9% saline). A 5% increase in lung function compared to placebo was predefined as clinically relevant. The primary outcome variable, the absolute change in FEV1 was not significantly affected by treatment over the study period. Exploratory analysis showed only a small effect on FEV1 at 3 months of treatment. Body weight, rate and time to pulmonary exacerbations, quality of life (QOL) total and respiratory score were not different. Safety was good, with no differences of adverse events, rate of premature withdrawals and change in laboratory parameters between treatment groups. In the GSH-group, both free and total GSH in sputum samples were increased after 3 and 6 months of treatment, however, cellular, inflammatory, redox-state and proteolytic markers remained unchanged. This study did not demonstrate a statistically significant effect of inhaled GSH on the primary endpoint FEV1. Other important secondary endpoints also did not change significantly with treatment. Inhaled glutathione was save at dose and duration applied.
. Results: The incidence of pts with 1 PDPE was 29% lower (p = 0.039) in the IDPM group than in the control group. Associated rescue antibiotic use incidence was reduced by 30% (p = 0.033), in the IDPM group vs. the control. The supportive positive trend of a 22% reduction in PDPE-related hospitalization incidence did not reach statistical significance (p = 0.219). The annualized PDPE rate was significantly lower in those patients treated with IDPM who had any improvement from baseline over 26 weeks in %-predicted FEV 1 (0.56 PDPE/year) compared to those who did not show FEV 1 improvement (1.36/year) (p = 0.03).
Conclusions:
PEs are a key driver of worsening lung function in CF, which is not restored to pre-exacerbation levels in up to 25% of cases. IDPM has an important impact on the rate of PEs, with a reduced risk seen predominantly in those patients who had also shown an improvement in pulmonary function. Objectives: Ciprofloxacin (CIP) is used to treat CF patients and is partly metabolised in the liver by the CYP3A4 enzyme. We investigated the correlation between the enzyme activity and the metabolism of CIP. A Monte Carlo simulation was performed to predict eventual treatment failure. Methods: We included 22 CF patients (21−53 yr) with chronic P. aeruginosa lung infections. The CYP3A activity was measured using the ERMBT. 500 mg CIP was given orally and blood samples were collected every half hour the first 3 h and at 6 and 12 h. The concentrations of CIP were calculated by using a biological assay. AUC, T max and C max were calculated. The Monte Carlo simulation was based on the MIC of 119 P. aeruginosa strains.
Results: A 14-fold variation, median (range), in AUC (mg·min/liter); 473.5 (138-1880) for CIP, a 30-fold variation in Cmax (mg/liter); 2 (0.25−7.6) and a 3 foldvariation in Tmax (min); 91 (46-153) was found.
We found an 8-fold variation in the CYP3A4 activity, with a median (range) of 0.8 (0.3−2.0), but no correlation with CIP metabolism was found. The Monte Carlo simulation showed that some of the patients did not reach concentrations high enough to eradicate the bacteria.
Conclusion:
We found a large variation in the metabolism of CIP and some patients may not have reached a high enough MIC/AUC ratio. We therefore recommend that plasma concentrations and MIC of the bacteria are measured regularly to avoid treatment failure. Conclusions: Continuous AZLI treatment was safe in Burk-infected CF pts and maintained FEV 1 above baseline for the first 24 wks of AZLI treatment in both AZLI-randomized pts and PBO pts crossing over to AZLI. Supported by Gilead Sciences
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